NR4A1 and breast cancer: In this regard, while 5–6% of BC patients exhibit bone metastases (BM) at the time of diagnosis, up to 65–75% of women with hormone-receptor-positive advanced BC develop skeletal lesions as the disease evolves, with consequent medical, social and economical repercussions [4,5].